Nomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and governmental agencies worldwide. It operates through three segments: Wealth Management, Investment Management, and Wholesale. The Wealth Management segment offers various financial products and investment consultation services. The Investment Management segment offers investment trust management, discretionary investment services, and investment funds. The Wholesale segment is involved in the sale, trading, agency execution, and market-making of fixed income and equity products, as well as structured financing and solutions. This segment also engages in underwriting various securities and other financial instruments, such as various classes of shares, convertible and exchangeable securities, investment grade and high yield debts, sovereign and emerging market debts, structured securities, and other securities; arranging private placements, as well as other capital raising activities; and provision of financial advisory services on business transactions comprising mergers and acquisitions, divestitures, spin-offs, capital structuring, corporate defense activities, leveraged buyouts, and risk solutions. The company was formerly known as The Nomura Securities Co., Ltd. and changed its name to Nomura Holdings, Inc. in October 2001. Nomura Holdings, Inc. was incorporated in 1925 and is headquartered in Tokyo, Japan.

Nomura Holdings Inc ADR American Depositary Shares

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $18.00. Tsao covers the ...

H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and Anapty...

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (N...

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA) and Weave Communic...

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA) and Weave Communications (WEAV)

In a report released on March 26, Fernando Garcia from RBC Capital maintained a Hold rating on SNAM S.p.A., with a price target of €6.40. The compa...

RBC Capital Reaffirms Their Hold Rating on SNAM S.p.A. (0NQP)

Native Mineral Resources Holdings Ltd. ( ($AU:NMR) ) has issued an announcement. Native Mineral Resources has reported additional high-grade gold i...

Native Mineral Resources Confirms Shallow High-Grade Gold at Podosky

Nomura Holdings received a Buy rating and price target from J.P. Morgan analyst today. In addition to J.P. Morgan, Nomura Holdings also received a ...

J.P. Morgan upgrades Nomura Holdings (NRSCF) to a Buy

Native Mineral Resources Holdings Ltd. ( ($AU:NMR) ) has provided an update. Native Mineral Resources has signed a binding term sheet with Haoma Mi...

Native Mineral Resources Secures Exclusive Mining Rights at Podosky Gold Deposit

Native Mineral Resources Holdings Ltd. ( ($AU:NMR) ) just unveiled an update. Native Mineral Resources has confirmed that all resolutions put forwa...

Native Mineral Resources Shareholders Reject Board and Name Changes at General Meeting

Barclays analyst Brendan Lynch maintained a Buy rating on Newmark Group today and set a price target of $19.00. According to TipRanks, Lynch is an ...

Current Quarter	$0.21	Next Quarter	$NA
Current Year	$0.83	Next Year	$0.75
QoQ Growth	NaN%	YoY Growth	-9.6%
3Y EPS CAGR	N/A	Target Price	$9.36
Consensus	Buy	Upside	+11.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NMR	$8.38	0.00%	2.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NMR	$8.38	0%	2.15M
3
4
5
6

NMR

NMR

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Nomura Holdings Inc ADR American Depositary Shares Data in Excel

Get Nomura Holdings Inc ADR American Depositary Shares Data in Excel